Uromodulin as a biomarker for lupus nephritis
Part of Cancer, Immune system & allergy, Kidney & urinary clinical trials.
This study looks at whether a protein called uromodulin (found in urine and blood) can help tell how active lupus nephritis is. It compares different groups of people with and without kidney problems to find better ways to diagnose and manage the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a diagnosis of systemic lupus erythematosus (SLE).
- You must have had a kidney biopsy showing lupus nephritis (for one group), OR have active lupus without kidney involvement, OR have inactive lupus, OR have another type of kidney disease (non-lupus), OR be a healthy volunteer.
- You must not be pregnant or breastfeeding.
- You must not have end-stage kidney disease, be on dialysis, or have had a kidney transplant.
- You must not have an active infection, sepsis, active cancer, or advanced heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a blood protein called uromodulin can help predict how well people with sepsis and acute kidney injury will do. Sepsis is a serious infection, and acute kidney injury is a sudden drop in kidney function. The results may help doctors better understand and manage this condition.
This study aims to find better ways to detect kidney problems in people with lupus by testing blood and urine samples. If you have lupus, you may help researchers improve how kidney disease is diagnosed and monitored.
This study looks at blood and urine markers that may show how active lupus kidney disease is and how it changes over time. It may help doctors better monitor people with active lupus-related kidney inflammation.
This study looks at whether a blood test for a specific antibody can help doctors understand how active lupus kidney disease is. It may help guide treatment decisions for people with lupus nephritis.
This study is looking for biomarkers (clues in your blood, urine, or tissue) that can help predict how well lupus nephritis (kidney inflammation caused by lupus) responds to treatment. It focuses on people who have active kidney disease and are either starting treatment or have been on a stable treatment for at least a month.
This study looks at whether certain substances in the blood, such as uric acid, homocysteine, and interleukin-17, are higher in people with lupus-related kidney disease compared to healthy individuals. It aims to find new ways to monitor or understand the condition better.
Hear when a new Uromodulin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.